Showing 201-210 of 3239 results for "".
- Patient Savings Program Available for Mylan's Doxycycline Hyclatehttps://practicaldermatology.com/news/20130925-patient_savings_program_available_for_mylans_doxycycline_hyclate/2459450/Patients who are prescribed Mylan's bioequivalent alternative to Doryx (doxycycline hyclate delayed-release tablets) USP for severe acne may be eligible for an instant savings program. Patients who take their prescriptions to participating pharmacies will receive an automatic co-pay reduction at the
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product
- Goldfaden MD to Donate to American Heart Association in 2013https://practicaldermatology.com/news/20121218-goldfaden_md_to_donate_to_american_heart_association_in_2013/2459656/Goldfaden MD plans to launch its Hands To Heart Anti-Aging Plus Brightening Hand Treatment in February 2013. In addition, ten percent of all proceeds from these purchases in February will be donated to the American Heart Association. The fast-
- Bovie Medical Promotes Double Warranty, Free Goodshttps://practicaldermatology.com/news/20121002-bovie_medical_promotes_double_warranty_free_goods/2459723/Bovie Medical Corporation started its Fall Festival of Fun promotion now through December 31, 2012. During the promotion, customers receive an increased value of a double warranty and free goods when purchasing the Aaron® 1250, Aaron® 2250, or Aaron® 3250. To find out more information contact a loca
- Mylan, Impax Win Ruling in Doryx Generics Patent Casehttps://practicaldermatology.com/news/20120502-mylan_impax_win_ruling_in_doryx_generics_patent_case/2459810/Mylan Inc. (MYL) said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn't infringe a patent held by Warner Chilcott (WCRX) Plc.
- DocBookMD App Offers Secure Communication, HIPAA Compliancehttps://practicaldermatology.com/news/20120424-docbookmd_app_offers_secure_communication_hipaa_compliance/2459816/Doctors can now send X-rays and lab results back and forth, securely and with full HIPAA compliance via a new application, available for iPhone, iPad, and Android. The DocBookMD app is free for doctors who are members of their state or county medical society. All activity is run through a secure ser
- Zasocitinib Could Raise the Efficacy Bar for Oral Psoriasis Treatment, Takeda Doctor Sayshttps://practicaldermatology.com/news/zasocitinib-could-raise-the-efficacy-bar-for-oral-psoriasis-treatment-takeda-doctor-says/2488520/Following the US Food and Drug Administration's decision to grant Priority Review to zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis, Chinwe Ukomad
- Analysis: Pediatric Allergic Rhinitis Doubled in Japan Over 40 Yearshttps://practicaldermatology.com/news/analysis-pediatric-allergic-rhinitis-doubled-in-japan-over-40-years/2487238/A 40-year epidemiologic analysis published in the World Allergy Organization Journal showed an increases in allergic rhinitis (AR), allergic conjunctivitis (AC), and Japanese cedar pollinosis (JCP) among school-aged children in western Japan, while rates of atopic dermatitis (AD) and bro
- First Patient Dosed with GPX4 Modulator Targeting Pathologic Senescent Cellshttps://practicaldermatology.com/news/First-Patient-Dosed-with-GPX4-Modulator-Targeting-Pathologic-Senescent-Cells/2474796/
- Phase 1 Trial Shows Safety and Dosing Potential for Combo IL-13 Therapy for ADhttps://practicaldermatology.com/news/phase-1-trial-shows-safety-and-dosing-potential-for-combo-il-13-therapy-for-ad/2471401/Apogee Therapeutics has reported positive interim results from a Phase 1 trial evaluating APG990, a subcutaneous, extended half-life monoclonal antibody targeting OX40L, for inflammatory and immunological conditions such as atopic dermatitis (AD), according to a pre